TTR and amyloidosis: An extremely high concentration of EGCG (43.6%, w/w) in the filling solution enabled the development of a stable drug candidate with improved bioavailability, according to preliminary studies in monkeys, and which meets the quality requirements for clinical trials, which, in this case, concerns cardiac transthyretin and light chain amyloidosis.